“Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S79. doi:10.25251/skin.2.supp.79.